Veingerl B
Department of Thoracic Surgery, Maribor Teaching Hospital, Maribor, Slovenia.
Wien Klin Wochenschr. 2001;113 Suppl 3:32-8.
The only method of treatment that offers a favourable prognosis for colorectal carcinoma is radical resection of a part of the colon or rectum including the pertinent lymph glands and radical removal of metastases. However, even such presumably curative surgery does not ensure full recovery, as recurrences are frequent and, according to several analyses, the 5-year survival rate is less than 50%. The most significant reason for this poor therapeutic success are residual micrometastases. Therefore, additional treatment strategies are attempted in several patients. Various prognostic factors of disease recurrence are known. One such prognostic sign is the serum carcinoembryonic antigen (CEA) level measured shortly after surgery.
All patients operated on electively for colorectal carcinoma at our institution within one year were followed. According to preoperative serum CEA levels, the patients were divided into a study group (preoperative CEA more than 10 ng/mL) and controls (preoperative CEA less than 10 ng/mL). In the former category, patients who underwent radical R0 resection were divided into three groups according to their postoperative serum CEA levels and CEA half-life: (CEA) R0-, (CEA) R1- and (CEA) R2-resected patients. All patients were then followed for 24 months; the number of recurrences and survival rates were registered.
A statistically significant difference in regard of survival and the number of recurrences was noted in patients divided according to the stage of disease, particularly between the three groups of patients from the study group undergoing curative surgery. After two years, survival was 96.97% in the CEA R0 group, 66.66% in the (CEA) R1 group and 50% in the (CEA) R2 group. Recurrences were as follows; 3.03% in (CEA) R0, 83.3% in (CEA) R1 and 100% in (CEA) R2.
The results of our study confirm the prognostic value of serum CEA measurement, in particular its half-life, following surgery for colorectal carcinoma.
对结直肠癌而言,唯一能带来良好预后的治疗方法是对部分结肠或直肠包括相关淋巴结进行根治性切除,并彻底清除转移灶。然而,即便进行了这种看似能治愈的手术,也无法确保完全康复,因为复发很常见,而且根据多项分析,5年生存率不到50%。治疗效果不佳的最主要原因是残留的微转移灶。因此,一些患者会尝试其他治疗策略。已知多种疾病复发的预后因素。其中一个预后指标是术后不久测得的血清癌胚抗原(CEA)水平。
对我院一年内择期接受结直肠癌手术的所有患者进行随访。根据术前血清CEA水平,将患者分为研究组(术前CEA超过10 ng/mL)和对照组(术前CEA低于10 ng/mL)。在前一组中,接受根治性R0切除的患者根据术后血清CEA水平和CEA半衰期分为三组:(CEA)R0切除患者、(CEA)R1切除患者和(CEA)R2切除患者。然后对所有患者随访24个月;记录复发次数和生存率。
根据疾病分期分组的患者在生存率和复发次数方面存在统计学显著差异,尤其是研究组中接受根治性手术的三组患者之间。两年后,CEA R0组的生存率为96.97%,(CEA)R1组为66.66%,(CEA)R2组为50%。复发情况如下:(CEA)R0组为3.03%,(CEA)R1组为83.3%,(CEA)R2组为100%。
我们的研究结果证实了血清CEA检测,特别是其半衰期,在结直肠癌手术后的预后价值。